Objective assessment of gait in xylazine-induced ataxic horses.

The research article discusses how the administration of the drug xylazine in horses induced a dose-dependent ataxia (loss of full control of bodily movements) and lead to significant changes in gait parameters. The study sought to understand these changes for a better evaluation of equine neurological disorders.

Methodology

• This study was conducted using a balanced, randomized, 2-way crossover design and involved eight horses who were assessed before and after the administration of xylazine at low and high dosages.
• Their gaits were analysed through kinematic data collected from a high-speed treadmill (both at a flat and 10% decline) and accelerometers that were placed on their head and sacrum.
• Kinetic data was also collected via a force plate to measure the forces produced by the horse’s motion.

Results

• The study found that all horses developed a dose-dependent ataxia following the administration of xylazine.
• There were significant increases in stride time, stride length, and time of contact with decreasing stride frequency following the administration of the drug.
• It was also observed that pelvic acceleration experienced a rise when the horses were made to walk on the treadmill, but it decreased when they walked over the ground after xylazine administration.
• There were significant modifications to the center of pressure and path length indices in the horses post the administration of the drug.

Conclusions

• Study’s limitations include the fact that it only examined one breed of horse (Arabian), all of the same height and weight. Plus, accelerometers were attached to the skin, not the bone, and there was no correction made for artefacts from skin displacement. The sedative drug effect is of a certain duration, which limited the data collection period.
• Despite the limitations, the research revealed that xylazine administration caused a dose-dependent ataxia in horses and resulted in substantial changes in gait parameters, pelvic accelerations, and stabilographic variables. Some of these changes were dose-dependent.
• Many of the altered gait parameters were probably a result of the overall slowing down of the stride cycle due to the sedative effect of xylazine.
• Given the findings, the authors recommend continued efforts to identify and evaluate quantifiable gait parameters susceptible to change following the development of clinical neurological disease in horses.